CX-717 – Kodiac biolabs

Plain-language summaryIntrigue 52 / 100

CX-717 is a methylsulfonyl benzoxazine ampakine investigated for ADHD and respiratory depression. The respiratory application was based on AMPA-mediated stimulation of central respiratory networks. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

49/100

The furthest-advanced CX-series ampakine, with real military human data but stalled Phase 2 development

Look, CX-717 is probably the most serious compound in the CX-series to ever see human volunteers, and that matters. Most ampakines from the Cortex Pharmaceuticals pipeline stayed in rodents or at best healthy volunteer Phase 1 work. CX-717 actually made it into DoD-funded sleep deprivation trials, and the published data from those studies is real: modest but reproducible improvements in vigilance and working memory during 24-72 hour sleep deprivation windows. Turner and colleagues published those results and they held up. Thats a bar that most research chemicals in this space never clear.

The mechanism here is AMPA receptor positive allosteric modulation. Specifically, CX-717 slows AMPA receptor deactivation and desensitization, which has downstream effects on synaptic strengthening, BDNF expression, and arousal-relevant circuitry. The benzoxazine class was specifically engineered to avoid the respiratory depression issues that dogged earlier ampakines like CX-516 and CX-614. That engineering worked, and the cleaner safety profile is part of why this one made it furthest in clinical development. AMPA PAM is not a new idea in 2025, but its still a genuinely interesting mechanism for cognitive enhancement and one the field hasn’t fully cracked at the translational level.

Where things get complicated is in the so-what question. CX-717 ran Phase 2 work in adult ADHD and the results were partial at best. The compound never advanced to Phase 3 or FDA review. That stall tells you something: the effect sizes weren’t compelling enough to justify continued development at commercial scale, or there were tolerability issues at higher doses that the low-impact class designation didn’t fully solve. We don’t know the full picture because incomplete pharma clinical data is rarely published cleanly.

As a bench tool, we think CX-717 has real but specialized utility. If you’re investigating AMPA-mediated plasticity, cognitive resilience under sleep debt, or BDNF upregulation pathways, having a compound with published human PK and real Phase 2 dose data is actually useful. You’re not working blind on the translational side. But if you want to study AMPA biology more broadly, newer PAMs with better characterized profiles exist and the competitive landscape has shifted since the early Cortex Pharmaceuticals era.

Honestly, the score here reflects a compound that showed genuine promise and cleared real bars that most research chemicals never approach, but ultimately hit a ceiling. The human signal is there; the effect size isn’t paradigm-defining. It sits comfortably in the worth-knowing, worth-studying-in-the-right-context zone rather than the immediately-prioritize-this tier.

Novelty: 40
Mechanism promise: 60
In-category differentiation: 52
Evidence quality: 50
Translational signal: 40
Research bench value: 48

Rationale CX-717 earns credit for being the most clinically advanced benzoxazine ampakine, with published DoD sleep-deprivation human data and Phase 2 ADHD work that most CX-series compounds never approached; however, the stalled development arc, modest effect sizes in published studies, and the maturity of the AMPA PAM class hold it solidly in established-active territory rather than novel-frontier.

Methylsulfonyl benzoxazine ampakine

A methylsulfonyl benzoxazine ampakine that advanced furthest of the CX-series in human trials, including military sleep deprivation studies.

Abstract

CX-717 (1-(N-methyl-N-methylsulfonyl-aminobenzoyl)pyrrolidine; CAS 412960-03-7) is a methylsulfonyl benzoxazine ampakine developed at Cortex Pharmaceuticals that advanced further in human trials than other CX-series compounds. The compound was studied by DARPA and the Department of Defense for cognitive performance maintenance during sleep deprivation in military personnel; published results showed modest but reproducible improvements in vigilance and working memory performance during 24- to 72-hour sleep deprivation. CX-717 was also studied for adult ADHD with partial Phase 2 results. The compound did not advance to FDA approval. Pharmacokinetics: plasma half-life approximately 3 to 4 hours; oral bioavailability adequate. The compound is sold as a research chemical with limited availability.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-057Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.